drugset / Trial / NCT01042678
Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with diabetic retinal edema.
Timeline
- Start
- 2010-02
- Primary completion
- 2010-12
- Completion
- 2010-12
Outcome
Outcome not reported
Stopped: “The study was terminated due to a company decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abicipar pegol | Protein / enzyme biologic | 0.04 mg | Intravitreal |
| Subject | Abicipar pegol | Protein / enzyme biologic | 0.15 mg | Intravitreal |
| Subject | Abicipar pegol | Protein / enzyme biologic | 0.4 mg | Intravitreal |
| Subject | Abicipar pegol | Protein / enzyme biologic | 1 mg | Intravitreal |
| Subject | Abicipar pegol | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Abicipar pegol | Protein / enzyme biologic | 3.6 mg | Intravitreal |